[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001266838A1 - Inhibitors of matriptase for the treatment of cancer - Google Patents

Inhibitors of matriptase for the treatment of cancer

Info

Publication number
AU2001266838A1
AU2001266838A1 AU2001266838A AU6683801A AU2001266838A1 AU 2001266838 A1 AU2001266838 A1 AU 2001266838A1 AU 2001266838 A AU2001266838 A AU 2001266838A AU 6683801 A AU6683801 A AU 6683801A AU 2001266838 A1 AU2001266838 A1 AU 2001266838A1
Authority
AU
Australia
Prior art keywords
matriptase
inhibitors
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266838A
Inventor
Robert B Dickson
Istvan Enyedy
Sheau-Ling Lee
Chen-Yong Lin
Shaomeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of AU2001266838A1 publication Critical patent/AU2001266838A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001266838A 2000-06-21 2001-06-12 Inhibitors of matriptase for the treatment of cancer Abandoned AU2001266838A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21307300P 2000-06-21 2000-06-21
US60/213,073 2000-06-21
PCT/US2001/018773 WO2001097794A2 (en) 2000-06-21 2001-06-12 Inhibitors of matriptase for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2001266838A1 true AU2001266838A1 (en) 2002-01-02

Family

ID=22793641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266838A Abandoned AU2001266838A1 (en) 2000-06-21 2001-06-12 Inhibitors of matriptase for the treatment of cancer

Country Status (3)

Country Link
EP (1) EP1355637A2 (en)
AU (1) AU2001266838A1 (en)
WO (1) WO2001097794A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797504B1 (en) 2000-09-08 2004-09-28 Dendreon San Diego Llc Inhibitors of serine protease activity of matriptase or MTSP1
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
DE50310038D1 (en) 2002-03-11 2008-08-07 Curacyte Ag INGREDIENTS OF UROKINASE, THEIR PREPARATION AND USE
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
DE10301300B4 (en) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
DE10322191B4 (en) 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylated amino acid derivatives, process for their preparation and their use
DE10342108A1 (en) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use
US7439226B2 (en) 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
KR101476458B1 (en) 2006-07-05 2015-01-05 카탈리스트 바이오사이언시즈, 인코포레이티드 Protease screening methods and proteases identified thereby
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
DE102008007440A1 (en) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amino acid derivatives as drugs
US8722930B2 (en) 2009-05-18 2014-05-13 Orion Corporation Protease inhibitors
US10175238B2 (en) * 2014-05-13 2019-01-08 Georgetown University Markers for abnormal cells
EP3558938A4 (en) * 2016-12-22 2020-08-19 Verlyx Pharma Inc. Amidine substituted analogues and uses thereof
CN112996529A (en) * 2018-10-02 2021-06-18 迪斯克医药公司 Matriptase 2 inhibitor and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH525896A (en) * 1961-09-11 1972-07-31 Wander Ag Dr A Cyclic bis-amidine cpds - esp useful as tuberculostats
AU4432597A (en) * 1996-09-25 1998-04-17 Regents Of The University Of California, The Methods of using agmatine to reduce intracellular polyamine levels and to inhibit inducible nitric oxide synthase
AU4679900A (en) * 1999-04-30 2000-11-17 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
DE60042245D1 (en) * 1999-11-16 2009-07-02 Oncozyme Pharma Inc PENTAMIDINE FOR THE TREATMENT OF CANCER
DE19955476A1 (en) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments

Also Published As

Publication number Publication date
WO2001097794A3 (en) 2003-08-21
EP1355637A2 (en) 2003-10-29
WO2001097794A2 (en) 2001-12-27
WO2001097794A8 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002223827A1 (en) Well treatment
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
AU2001266068A1 (en) Treatment of mineral substrates
AU2001227966A1 (en) Methods for treating tumors
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AUPQ923100A0 (en) Treatment of prostate cancer
EP1176964B8 (en) Uses of et743 for treating cancer
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU2001293891A1 (en) New combination for the treatment of asthma
AU2002217447A1 (en) Apparatus for lipolysis for aesthetic treatment
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU2001253836A1 (en) Method of treating cancer
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer